IN THE CLAIMS

1. (Currently Amended) A method to inhibit angiogenesis in vivo, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 receptor signal transduction, wherein the antagonist inhibits phosphorylation of T^{236} of the EDG-1 receptor.

2-8. (Cancelled)

9. (Currently Amended) A method for treatment of unwanted angiogenesis in a human or animal, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 receptor signal transduction, wherein the antagonist inhibits phosphorylation of T^{236} of the EDG-1 receptor.

10-12. (Cancelled)

13. (New) The method of claim 1, wherein the antagonist inhibits a PI-3 kinase.

14. (New) The method of claim 1, wherein the antagonist inhibits chemotaxis of a cell expressing the EDG-1 receptor.

15. (New) The method of claim 14, wherein the antagonist inhibits the formation of cortical actin structures.

16. (New) The method of claim 1, wherein the antagonist is a small molecule.

17. (New) The method of claim 9, wherein the antagonist inhibits a PI-3 kinase.

18. (New) The method of claim 9, wherein the antagonist inhibits chemotaxis of a cell expressing the EDG-1 receptor.

19. (New) The method of claim 18, wherein the antagonist inhibits the formation of cortical actin structures.

20. (New) The method of claim 9, wherein the antagonist is a small molecule.

21. (New) A method of determining if a compound inhibits angiogenesis, comprising determining if the compound decreases Akt kinase phosphorylation of T^{236} of an EDG-1 receptor.

22. (New) The method of claim 21, wherein determining comprises determining the level of phosphorylation of T^{236} of the EDG-1 receptor in the presence and absence of the compound.

23. (New) The method of claim 21, wherein determining comprises determining the level of Akt-EDG-1 association in the presence and absence of the compound.

24. (New) The method of claim 21, wherein determining comprises determining the effect of the compound on cortical actin structure formation.

25. (New) The method of claim 21, wherein determining comprises assaying CHO cells expressing EDG-1 for cell migration.

26. (New) The method of claim 21, wherein determining is performed in vitro.